News

This approval marks the first country approval in the world for SKYRIZI. “With this first global approval of SKYRIZI, we are excited to bring a new treatment option

Under the terms of the extension agreement, Transgene will contribute its industry-leading OV design and engineering expertise, some non-antibody transgenes, as well as its proprietary engineered vaccinia virus

The open-label mid-stage trial of SFX-01, which was launched in January 2017, was carried out in 46 patients with estrogen-positive (ER+) metastatic breast cancer. SFX-01 is a synthetic

This is the first approval of Forxiga for the treatment of patients with T1D. Elisabeth Björk, Senior Vice President, Head of late Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals,

The companies have reached settlement more than five years after the litigation started with Xarelto. During the period, all six cases related to Xarelto went to trial. Bayer

The trial, called ARTEMIS, demonstrated that the proportion of patients treated with AR101 who could tolerate a 1,000mg dose of peanut protein, was significantly higher than what was

The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as

“Today’s submission brings us one step closer to our goal of improving treatment outcomes for people newly diagnosed with multiple myeloma,” said José Antonio Burón Vidal, VP Medical

Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.